Aliro announced today that AliroNet® has been named a Gold winner in the 21st Annual 2025 Globee Awards for Cybersecurity. This prestigious awards program honors excellence and innovation in ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

PortX, a leading financial infrastructure and integration technology company that provides open access to the core and drives innovation for financial institutions with its ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers ...

Armis previously achieved FedRAMP Moderate and DISA IL4 authorizations in 2023. “With the explosion of connected assets, Federal entities must ensure their entire attack surface is defended and ...

Depleting IL-4 from the IL-3-exposed basophil supernatant reduced its positive effects on CTLs. Further, IL-3 injections in tumor-bearing mice lacking IL4 had no impact on tumor growth, confirming a ...

Our first candidate nominated for AIID is ZW1528, which is an IL4 receptor alpha by IL33 bispecific, which we believe to be beneficial for the treatment of respiratory inflammation such as mixed ...

Dupixent, a blockbuster anti-IL4-alpha antagonist, was cleared for the lung condition after Phase III trials demonstrated a 30% to 34% drop in the rate of exacerbations versus placebo. In April 2024, ...